Skip to main content

Table 3 Targets in the tumor angiogenesis and targeted imaging agents in HNSCC

From: Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma

Targets

Targeted Imaging Agent

Results

Imaging Technique

Refs.

Integrins

18F-Galacto-RGD

Image fusion of 18F-Galacto-RGD PET with MRI or multi-slice CT allows for definition of tumor subvolumes with intense tracer uptake

PET

[107]

68Ga-DOTA-E-[c(RGDfK)]2

Could detect αvβ3 integrin expression in OSCC patients with adequate TBRs

PET/CT

[108]

68Ga-NODAGA-RGD

68Ga-NODAGA-RGD uptake has a different spatial distribution than 18F-FDG bringing different tumor information, and is not related to tumor grade, p16, or HPV status

PET/CT

[109]

111In-RGD2

Allows in vivo monitoring of angiogenic responses after radiotherapy, and its uptake in HNSCC was not affected by anti-angiogenic drug therapy

PET/CT

[111]

68Ga-NODAGA-c(RGDfK)

Uptake of radiolabeled RGD peptides is not necessarily decreased by effective bevacizumab antiangiogenic therapy

PET/CT

[112]

18F-RGD-K5

Demonstrates the feasibility of identifying incomplete response to concurrent CRT in HNSCC patients using RGD PET/CT

PET/CT

[113]

PSMA

111In-J591

Has potential as a targeting agent for solid tumor vasculature and lesion detection in HNSCC

gamma camera & SPECT

[120]

68Ga-PSMA

Case report of incidental detection of oropharynx SCC

PET/CT

[121]

68Ga-PSMA

Detection of synchronous primary tongue base SCC in patients with prostate cancer

PET/CT

[122]

  1. 111In Indium-111, 18F-FDG Fluorine-18 Fluorodeoxyglucose, 68Ga Gallium-68, CRT chemoradiotherapy, CT  computed tomography, HNSCC head and neck squamous cell carcinoma, HPV human papilloma, MRI  magnetic resonance imaging, OSCC oral squamous cell carcinoma, PET  positron emission tomography, PSMA prostate-specific membrane antigen, RGD arginine glycine aspartic acid virus, SCC  squamous cell carcinoma, TBR tumor-to-background ratio